For UK MedTech companies
Clinicians who could refer to your device simply are not doing so
Without embedded referral pathways, even a clinically superior device stays peripheral to the workflows that determine patient access. The gap is rarely clinical evidence, it is structural familiarity.
Two minutes. Solva follows up with specific clinical network options.
- Low rates of clinician-initiated referrals for the MedTech product
- Difficulty in securing meetings with key clinical decision-makers
- Limited understanding among clinicians of the product's benefits and integration
- Slow or stagnant growth in product usage despite initial interest
- Inefficient product launch and adoption cycles
- Strained relationships with healthcare professionals and institutions
- Reduced revenue and market share for MedTech companies
- Increased marketing and sales costs due to inefficient adoption
- Delayed patient access to innovative treatments
- Suboptimal patient outcomes due to lack of advanced technology integration
- Perception of MedTech companies as difficult to work with
- Negative impact on brand image and trust within the healthcare community
Fragmented NHS engagement is a significant challenge for SMEs developing digital health products in the UK. (CPI, 2025)
Source: https://www.uk-cpi.com/challenges-and-opportunities-for-the-uk-medtech-sme-ecosystem-2025
Frequently asked questions
Why does this problem persist?
Building clinical referral networks requires direct engagement with healthcare professionals, understanding their workflows, and demonstrating clear clinical benefits. MedTech companies often struggle to gain access to busy clinicians and integrate their solutions seamlessly into existing patient pathways, hindering adoption and referrals.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.